Cytek Biosciences Announces $50 Million Stock Repurchase Program
May 19, 2023 09:00 ET
|
Cytek Biosciences, Inc.
FREMONT, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved the...
Cytek® Biosciences Marks Shipment of Its 100th Cell Sorter as the Company Continues to Lead Cell Analysis Forward
May 16, 2023 08:00 ET
|
Cytek Biosciences, Inc.
FREMONT, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that it has shipped its 100th Cytek Aurora CS...
Cytek Biosciences Reports First Quarter 2023 Financial Results
May 09, 2023 16:05 ET
|
Cytek Biosciences, Inc.
FREMONT, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the first quarter ended March 31,...
Cytek Biosciences to Report First Quarter 2023 Financial Results on May 9, 2023
April 20, 2023 16:05 ET
|
Cytek Biosciences, Inc.
FREMONT, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter...
Cytek® Biosciences Introduces New 20-Color AML Panel
March 07, 2023 17:00 ET
|
Cytek Biosciences, Inc.
FREMONT, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the launch of a new 20-Color Acute Myeloid...
Cytek Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023 16:05 ET
|
Cytek Biosciences, Inc.
Full year 2022 revenue increased 28%, or 34% on constant currency basis, compared to prior year Provides full year 2023 revenue guidance of $225 million to $235 million, or growth of 37% to 43% over...
Sale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences Completed
February 28, 2023 09:21 ET
|
Cytek Biosciences, Inc.
SALUGGIA, Italy, and FREMONT, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly...
Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin
February 13, 2023 16:07 ET
|
Cytek Biosciences, Inc.
Sale of assets related to Flow Cytometry & Imaging (FCI) Business UnitAcquisition will expand Cytek’s product portfolio to include imaging and menu-based application driven flow cytometry to...
Cytek Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
February 07, 2023 16:05 ET
|
Cytek Biosciences, Inc.
FREMONT, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter...
Cytek® Biosciences Partners with Bio-Rad to Expand Reagent Portfolios
February 07, 2023 09:00 ET
|
Cytek Biosciences, Inc.
FREMONT, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Delivering a boost to immuno-oncology and immunotherapy researchers, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that it has entered...